Loading…
Loading…
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure with 155 holdings, whereas VanEck Pharmaceutical ETF is concentrated in 26 major drugmakers.
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
The State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio and higher assets under management than the VanEck Pharmaceutical ETF VanEck Pharmaceutical ETF focuses exclusively on pharmaceuticals while State Street Health Care Select Sector SPDR ETF covers medical equipment and healthcare services Historical data shows VanEck Pharmaceutical ETF has delivered higher 5-year growth but also experienced a deeper maximum drawdown